WOUND MGMT TECS IN COM STK USD (WNDM)

FORT WORTH, Texas, Nov. 20 /PRNewswire-FirstCall/ -- Wound Care
Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (WNDM),
announced today a published case demonstrating the efficacy of their advanced
wound care collagen product, CellerateRx(R). The case was presented in the
November/December 2008 issue of Podiatry Management in the special section,
Diabetic Wound Care Management on the Leading Edge: Case Presentations from
APWCA, APWCA Case #1: Using Combined Treatment Modalities for Successful Wound
Healing. The case was by Jane Fore, MD, a board certified internist and
certified wound care specialist, whose practice is totally dedicated to the
healing of challenging wounds.

"We are very excited about the unsolicited case published in this month's
edition of Podiatry Management," states Cathy Bradshaw, President of Wound
Care Innovations. "Diabetic foot wounds with infections can be complicated
and can require multiple approaches to treatment. This case demonstrates the
biocompatibility of CellerateRx(R) in supporting the successful take of living
skin equivalents and the delivery of antimicrobials when used in combinational
therapies. The article further reports CellerateRx's(R) effectiveness in
treating tunneling wounds, and is easy to use. Packing and unpacking these
tunneling wounds can be very painful for the patient. CellerateRx(R) is
biodegradable and does not need to be removed from the wound. We are delighted
to be able to provide to the market a unique, patented advanced wound care
collagen product to assist in the management of these difficult wounds."

Diabetic wounds are problematic for patients and a drain on the healthcare
industry. In the United States, it is estimated that 15-20% of diabetics will
develop a foot ulcer in their lifetime and that 14-24% of these ulcers will
result in amputations. Every 30 seconds a leg is lost to diabetes somewhere
in the world.

CellerateRx(R) is FDA cleared for acute and chronic wounds which include
but are not limited to: diabetic ulcers, venous stasis ulcers, ulcers due to
arterial insufficiency, pressure ulcers stages I-IV, surgical wounds,
traumatic wounds, superficial wounds, and 1st and 2nd degree burns. It comes
in two forms, a powder which is about 95% collagen, and a gel which is about
65% collagen, and contains no additives or synthetics. CellerateRx(R) is
manufactured in the United States.

About Wound Management Technologies, Inc.:

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its
corporate headquarters in Fort Worth, Texas, markets and distributes wound
care products to the healthcare market under patented technology licensed to
the Company. The Company is positioned and seeks to be a leading provider of
wound care products. For more information on the Company please visit the
Company's Website at www.Celleraterx.com .

"Safe Harbor" Statement: Under The Private Securities Litigation Reform
Act of 1995: The statements in the press release that relate to the company's
expectations with regard to the future impact on the company's results from
new products in development are "forward-looking statements," within the
meaning of the Private Securities Litigation Reform Act of 1995. Since this
information may contain statements that involve risk and uncertainties and are
subject to change at any time, the company's actual results may differ
materially from expected results. This document may contain forward-looking
statements concerning the Company's operations, current and future performance
and financial condition. These items involve risks and uncertainties such as
product demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, the ability to consummate and integrate
acquisitions, and other risks and uncertainties detailed in the Company's SEC
filings. The Company undertakes no obligation to revise any of these
statements to reflect the future circumstances or the occurrence of
unanticipated events.

SOURCE Wound Management Technologies, Inc.